Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of
hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome
coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.